• Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging

    Tuesday October 12th 2021

  • Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development

    Tuesday October 12th 2021

  • KU Leuven develops very potent antiviral against dengue

    Thursday October 7th 2021

  • OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Thursday September 30th 2021

  • Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)

    Wednesday September 29th 2021

  • Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study

    Wednesday September 22nd 2021

  • Mithra announces an update on PeriNesta®

    Wednesday September 22nd 2021

  • Galapagos announces positive CHMP opinion for Jyseleca® (filgotinib) for the treatment of adults with moderately to severely active ulcerative colitis

    Friday September 17th 2021

  • Your news here?

  • Flamingo Therapeutics expands alliance with Ionis Pharmaceuticals to develop RNA-targeted therapies for oncology

    Thursday September 9th 2021

  • Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases

    Thursday September 9th 2021

  • ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV infected pigs

    Thursday September 9th 2021

Strategic Partners